GlassScriptPhysician profile
Ambrose Aboud
NPI 1407843873
$1,290.33
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $752.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $778.14 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $356.31 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $44.96 | 2019 | |
| Genzyme Corporation | $30.13 | 2019 | |
| Merck Sharp & Dohme LLC | $24.58 | 2019 | |
| Novo Nordisk INC | $18.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.92 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.24 | 2019 | |
| Pfizer INC. | $11.05 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ambrose Aboud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.